KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Net Margin (2016 - 2025)

Historic Net Margin for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to 22.15%.

  • Emergent BioSolutions' Net Margin fell 169200.0% to 22.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.62%, marking a year-over-year increase of 323000.0%. This contributed to the annual value of 18.26% for FY2024, which is 542100.0% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Net Margin of 22.15% as of Q3 2025, which was down 169200.0% from 8.52% recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Net Margin peaked at 39.07% during Q3 2024, and registered a low of 566.2% during Q2 2024.
  • Moreover, its 5-year median value for Net Margin was 11.42% (2021), whereas its average is 44.76%.
  • Per our database at Business Quant, Emergent BioSolutions' Net Margin crashed by -4888400bps in 2024 and then skyrocketed by 5576800bps in 2025.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Net Margin stood at 24.27% in 2021, then crashed by -184bps to 20.29% in 2022, then grew by 12bps to 17.9% in 2023, then rose by 10bps to 16.08% in 2024, then soared by 238bps to 22.15% in 2025.
  • Its Net Margin stands at 22.15% for Q3 2025, versus 8.52% for Q2 2025 and 30.6% for Q1 2025.